Timothy Yap is a Cancer Research UK Clinical Research Fellow in the Drug Development Unit at The Royal Marsden Hospital, UK. He is currently completing a Ph.D. in molecular pharmacology at The Institute of Cancer Research, UK.
Dr. Yap’s research focuses on the discovery of targeted therapies and accelerating their development with novel predictive and pharmacodynamic biomarkers. He has been closely involved in the preclinical development of Akt inhibitors and early clinical trials of multiple targeted agents, including the PARP inhibitor olaparib in BRCA-mutated cancers, the prostate cancer drug abiraterone, and agents targeting HER2, EGFR, IGF1R, MET and the PI3K–Akt–mTOR pathway.
Page last modified: